A Development of Synthetic Chimeric Peptide Against Human Papillomavirus 16 L1, L2, E6 And E7 PeptidesBased Therapeutic Potential in A Murine Model of Cervical Cancer |Biomedgrid

The human papillomavirus (HPV), which causes cervical cancer, is the fourth most frequent disease in women globally. Although there are HPV preventative vaccines available, they have no therapeutic benefits and do not treat pre-existing infections. The goal of this research is to create a cervical cancer therapeutic vaccination. The target antigens for epitope prediction were the E6 and E7 oncoproteins from HPV16. The best epitopes were chosen based on antigenicity, allergenicity, and toxicity. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted. In our study, software predicted, multiple H-2Db restricted HPV16 cytotoxic T lymphocytes (CTL) epitopes on a synthetic chimeric peptide, was used along with different immunopotentiating adjuvants such as heat-killed Mycobacterium w (Mw) cells. In vitro TC-1 tumour cells expressing HPV16 E6 and E7 were able to be destroyed by CTL through subcutaneous immunisation with H-2Db-restricted HPV16 peptide, and C57BL/6 mice were also protected from in vivo challenge with TC-1 cells. This chimeric peptide performed best in vitro when combined with a peptide mixture that included Mw as an adjuvant. Thus, this strategy may offer a possible peptide-based therapeutic candidate vaccination for the prevention of cervical cancer caused by HPV infection.